Merck Data Could Support Use Of PD-L1 Biomarker In Lung Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Data suggest the biomarker could be useful in lung cancer to help identify the 25% of patients who benefit the most, according to data presented at the American Association for Cancer Research meeting. But the biomarker looks less useful in melanoma.
You may also be interested in...
Big Pharma Explores New Frontier Of Lung Cancer Immunotherapy
Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.